554 related articles for article (PubMed ID: 19615940)
21. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Rini BI; Stenzl A; Zdrojowy R; Kogan M; Shkolnik M; Oudard S; Weikert S; Bracarda S; Crabb SJ; Bedke J; Ludwig J; Maurer D; Mendrzyk R; Wagner C; Mahr A; Fritsche J; Weinschenk T; Walter S; Kirner A; Singh-Jasuja H; Reinhardt C; Eisen T
Lancet Oncol; 2016 Nov; 17(11):1599-1611. PubMed ID: 27720136
[TBL] [Abstract][Full Text] [Related]
22. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
[TBL] [Abstract][Full Text] [Related]
24. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.
Motzer RJ; Hutson TE; Olsen MR; Hudes GR; Burke JM; Edenfield WJ; Wilding G; Agarwal N; Thompson JA; Cella D; Bello A; Korytowsky B; Yuan J; Valota O; Martell B; Hariharan S; Figlin RA
J Clin Oncol; 2012 Apr; 30(12):1371-7. PubMed ID: 22430274
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.
Atkinson BJ; Kalra S; Wang X; Bathala T; Corn P; Tannir NM; Jonasch E
J Urol; 2014 Mar; 191(3):611-8. PubMed ID: 24018239
[TBL] [Abstract][Full Text] [Related]
26. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C
Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522
[TBL] [Abstract][Full Text] [Related]
27. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
Méjean A; Ravaud A; Thezenas S; Colas S; Beauval JB; Bensalah K; Geoffrois L; Thiery-Vuillemin A; Cormier L; Lang H; Guy L; Gravis G; Rolland F; Linassier C; Lechevallier E; Beisland C; Aitchison M; Oudard S; Patard JJ; Theodore C; Chevreau C; Laguerre B; Hubert J; Gross-Goupil M; Bernhard JC; Albiges L; Timsit MO; Lebret T; Escudier B
N Engl J Med; 2018 Aug; 379(5):417-427. PubMed ID: 29860937
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of sunitinib for advanced non-clear cell renal cell carcinoma.
Shi HZ; Tian J; Li CL
Asia Pac J Clin Oncol; 2015 Dec; 11(4):328-33. PubMed ID: 26471774
[TBL] [Abstract][Full Text] [Related]
29. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
[TBL] [Abstract][Full Text] [Related]
30. [Sunitinib in clinical practice: the expanded access program for metastatic renal cell carcinoma].
Marschner N
Onkologie; 2010; 33 Suppl 1():12-4. PubMed ID: 20164671
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
Li XS; Wu X; Zhao PJ; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; Wang G; He ZS; Zhou LQ; Jin J
Chin Med J (Engl); 2011 Sep; 124(18):2920-4. PubMed ID: 22040503
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and toxicity of sunitinib for non clear cell renal cell carcinoma (RCC): a systematic review of the literature.
Abdel-Rahman O; Fouad M
Crit Rev Oncol Hematol; 2015 May; 94(2):238-50. PubMed ID: 25638704
[TBL] [Abstract][Full Text] [Related]
33. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.
Tannir NM; Plimack E; Ng C; Tamboli P; Bekele NB; Xiao L; Smith L; Lim Z; Pagliaro L; Araujo J; Aparicio A; Matin S; Wood CG; Jonasch E
Eur Urol; 2012 Dec; 62(6):1013-9. PubMed ID: 22771265
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
[TBL] [Abstract][Full Text] [Related]
35. [Clinical study of Sunitinib in the treatment of metastatic renal clear cell carcinoma: a single center 23 cases experience].
Li XS; Song Y; Gong K; Zhang Q; Yu W; Song G; Zhao Z; Zhang Z; Wang G; Zhou LQ; He ZS; Jin J
Zhonghua Wai Ke Za Zhi; 2010 Mar; 48(5):375-7. PubMed ID: 20450612
[TBL] [Abstract][Full Text] [Related]
36. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
Bracarda S; Iacovelli R; Boni L; Rizzo M; Derosa L; Rossi M; Galli L; Procopio G; Sisani M; Longo F; Santoni M; Morelli F; Di Lorenzo G; Altavilla A; Porta C; Camerini A; Escudier B;
Ann Oncol; 2015 Oct; 26(10):2107-13. PubMed ID: 26216384
[TBL] [Abstract][Full Text] [Related]
37. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
Choueiri TK; Halabi S; Sanford BL; Hahn O; Michaelson MD; Walsh MK; Feldman DR; Olencki T; Picus J; Small EJ; Dakhil S; George DJ; Morris MJ
J Clin Oncol; 2017 Feb; 35(6):591-597. PubMed ID: 28199818
[TBL] [Abstract][Full Text] [Related]
38. Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan.
Miyake H; Miyazaki A; Harada K; Fujisawa M
Med Oncol; 2014 Jun; 31(6):978. PubMed ID: 24793747
[TBL] [Abstract][Full Text] [Related]
39. Sunitinib in metastatic renal cell carcimoma: a single-center experience.
Krishna VM; Noronha V; Prabhash K; Joshi A; Patil V; Bhosale B; Ravi T; Menon H; Gupta S; Banavali SD; Bakshi G; Tangaonkar HB
Indian J Cancer; 2013; 50(3):268-73. PubMed ID: 24061470
[TBL] [Abstract][Full Text] [Related]
40. Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial.
Yildiz I; Ekenel M; Akman T; Kocar M; Uysal M; Kanitez M; Varol U; Bayoglu IV; Tural D; Kaplan MA; Avci N; Sürmeli Z; Dede İ; Ulaş A; Yazici O; Basaran M
Anticancer Res; 2014 Aug; 34(8):4329-34. PubMed ID: 25075067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
